Synektik SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLSNKTK00019
PLN
270.20
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Strong Long Term Fundamental Strength with a 69.40% CAGR growth in Operating Profits

  • Company has a low Debt to Equity ratio (avg) at times
  • The company has been able to generate a Return on Capital Employed (avg) of 81.43% signifying high profitability per unit of total capital (equity and debt)
2

With ROE of 54.71%, it has a attractive valuation with a 11.31 Price to Book Value

3

Consistent Returns over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 2,354 Million (Small Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.99%

stock-summary
Debt Equity

-0.28

stock-summary
Return on Equity

56.18%

stock-summary
Price to Book

10.57

Revenue and Profits:
Net Sales:
154 Million
(Quarterly Results - Jun 2025)
Net Profit:
31 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.37%
0%
15.37%
6 Months
21.93%
0%
21.93%
1 Year
40.88%
0%
40.88%
2 Years
212.01%
0%
212.01%
3 Years
712.63%
0%
712.63%
4 Years
828.52%
0%
828.52%
5 Years
900.74%
0%
900.74%

Synektik SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
40.29%
EBIT Growth (5y)
69.40%
EBIT to Interest (avg)
19.18
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
3.14
Tax Ratio
20.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
81.43%
ROE (avg)
23.83%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
11.31
EV to EBIT
15.95
EV to EBITDA
13.86
EV to Capital Employed
13.51
EV to Sales
3.42
PEG Ratio
0.73
Dividend Yield
3.25%
ROCE (Latest)
84.69%
ROE (Latest)
54.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 23.66% vs -38.60% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 38.64% vs -33.53% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "154.20",
          "val2": "124.70",
          "chgp": "23.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "42.30",
          "val2": "35.20",
          "chgp": "20.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "2.60",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "30.50",
          "val2": "22.00",
          "chgp": "38.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "239.80%",
          "val2": "241.00%",
          "chgp": "-0.12%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 39.65% vs 167.77% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 57.33% vs 409.71% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "624.10",
          "val2": "446.90",
          "chgp": "39.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "123.70",
          "val2": "84.00",
          "chgp": "47.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.90",
          "chgp": "-26.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.30",
          "val2": "-1.70",
          "chgp": "23.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "82.60",
          "val2": "52.50",
          "chgp": "57.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "171.80%",
          "val2": "155.00%",
          "chgp": "1.68%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
154.20
124.70
23.66%
Operating Profit (PBDIT) excl Other Income
42.30
35.20
20.17%
Interest
0.00
2.60
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
30.50
22.00
38.64%
Operating Profit Margin (Excl OI)
239.80%
241.00%
-0.12%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 23.66% vs -38.60% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 38.64% vs -33.53% in Mar 2025

Annual Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
624.10
446.90
39.65%
Operating Profit (PBDIT) excl Other Income
123.70
84.00
47.26%
Interest
1.40
1.90
-26.32%
Exceptional Items
-1.30
-1.70
23.53%
Consolidate Net Profit
82.60
52.50
57.33%
Operating Profit Margin (Excl OI)
171.80%
155.00%
1.68%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2024 is 39.65% vs 167.77% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 57.33% vs 409.71% in Sep 2023

stock-summaryCompany CV
About Synektik SA stock-summary
stock-summary
Synektik SA
Pharmaceuticals & Biotechnology
Synektik SA is a Poland-based company active in the medical sector. It produces PACS software which allows running a diagnostic imaging laboratory. It runs a research laboratory which performs acceptance and specialist tests of X-ray equipment. The Company sells medical equipment and operates a services center for imaging equipment. Synektik SA is a partner of Siemens. On November 28, 2013, the Company raised its stake in Miedzynarodowe Centra Medyczne Inwestycje Sp z o o to 100%.
Company Coordinates stock-summary
Company Details
Al. Witosa 31 , WARSZAWA None : 00-710
stock-summary
Tel: 48 22 3270900
stock-summary
Registrar Details